Standard adjuvant therapy for adrenocortical carcinoma

Alfredo Berruti, MD, University of Brescia, Brescia, Italy, talks on standard adjuvant therapy for patients with adrenocortical carcinoma. Adjuvant therapy is the standard for patients with adrenocortical carcinoma at high-risk of relapse following surgery. Patients with adrenocortical carcinoma at low-intermediate risk are a minority. The results of the Ajuvo trial showed this patient population have a far better survival outcome and do not benefit from adjuvant mitotane. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.